Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.45 |
| ▸ | FNTB | P49356 | 4/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4280884 | 0.69 | FNTA (0.78) | FNTAFNTB | |
| SCHEMBL18754515 | 0.68 | FNTA (0.53) | FNTAFNTBRORC | |
| SCHEMBL254428 | 0.68 | HPGD (0.53) | SCN4ANPSR1 | |
| SCHEMBL11357003 | 0.67 | TAS1R3 (0.42) | FFAR1SCN4A | |
| SCHEMBL5089019 | 0.66 | HRH3 (0.43) | FNTAFNTB | |
| SCHEMBL4378944 | 0.66 | FNTA (0.49) | FNTAFNTB | |
| SCHEMBL10932267 | 0.66 | TAS1R3 (0.42) | FFAR1RORC | |
| SCHEMBL7759203 | 0.66 | SLC2A1 (0.46) | — | |
| SCHEMBL5778239 | 0.65 | FNTA (0.68) | FNTAFNTB | |
| SCHEMBL25621298 | 0.65 | TAS1R3 (0.45) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1267872-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTI-TUMOR ANTHRACYCLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001064197-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTI-TUMOR ANTHRACYCLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |